IMVT-1402 (imeroprubart)

Sept. 23, 2026: Immunovant (NASDAQ: IMVT) reported topline results from Period 1 of a proof-of-concept trial of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). The randomized, double-blind, placebo-controlled global study (NCT06980805) enrolled 57 adults and evaluated percent change from baseline in CLASI-A score at Week 12 as the primary endpoint.

The study did not achieve statistical significance on the primary endpoint. Immunovant said numerical trends favored IMVT-1402 over placebo across multiple endpoints, and patients with deeper IgG reductions from baseline were more likely to show improved clinical responses. IMVT-1402 showed a favorable safety and tolerability profile consistent with prior studies.

Despite these signals, Immunovant said the results did not meet its internal bar and, citing the competitive landscape and the clinical results observed, plans to stop development of IMVT-1402 in CLE. The company said all other clinical development timelines for IMVT-1402 remain on track, including programs in Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjogren’s disease.